Empyrean Therapeutics, Inc. | WebDisclosure

Basculer en Français

10713	Companies
229446	Keywords
158044	Articles
121874	Press releases

Headlines Articles Press releases Empyrean Therapeutics, Inc.

Home
Companies
Empyrean Therapeutics, Inc.

BRIEF

published on 11/25/2024 at 23:25, 1 year 7 months ago

Empyrean Therapeutics Acquires Novel Cancer Treatment Molecule

Cancer Treatment Pharmaceutical Acquisition Empyrean Therapeutics TLR-2 Antagonist R&D Innovation
BRIEF

published on 11/25/2024 at 23:25, 1 year 7 months ago

Empyrean Therapeutics acquiert une nouvelle molécule pour le traitement du cancer

Traitement Du Cancer Acquisition Pharmaceutique Thérapeutique Empyrean Antagoniste Du TLR-2 Innovation En R&D
PRESS RELEASE

published on 11/25/2024 at 23:20, 1 year 7 months ago

Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies to Advance and Commercialize Breakthrough Cancer Treatment
Empyrean Therapeutics, Inc. acquires novel cancer drug molecule EMS-312 from Eos Therapies, aiming to expedite development for brain, pancreatic, breast, and hard-to-treat cancers. Strategic move marks milestone. CEOs Kal Fishman and Doug Bonhaus express optimism

Empyrean Therapeutics Novel Cancer Drug EMS-312 Eos Therapies CEO Kal Fishman

Accesswire

Published on 07/14/2026 at 01:45, 2 hours 46 minutes ago

Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 4 hours 30 minutes ago

Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 5 hours 21 minutes ago

Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 6 hours 56 minutes ago

ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 8 hours 31 minutes ago

IBC Announces Share-Based Compensation to Directors

View all ACCESSWIRE

EQS Group

Published on 07/13/2026 at 22:30, 6 hours 1 minute ago

Half-year 2026 Results Media and Investor Conference Call and Webcast
Published on 07/13/2026 at 21:20, 7 hours 11 minutes ago

Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 21:17, 7 hours 13 minutes ago

EQS-Adhoc: Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 20:48, 7 hours 43 minutes ago

EQS-Adhoc: Gateway Real Estate AG: Forecast for the financial year 2026
Published on 07/13/2026 at 20:23, 8 hours 8 minutes ago

EQS-Adhoc: TRATON SE: Preliminary operating result for Q2 2026 exceeds market expectations

Les Echos

Published on 07/13/2026 at 18:00, 10 hours 31 minutes ago

CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 10 hours 31 minutes ago

PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 10 hours 31 minutes ago

THERMADOR GROUPE : 2026 half-year turnover
Published on 07/13/2026 at 18:00, 10 hours 31 minutes ago

THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
Published on 07/13/2026 at 17:45, 10 hours 46 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE